Nilsson Gunnar H, Björholt Ingela, Johnsson Hans
Department of Medicine, Research Unit of General Practice, Karolinska Institutet, Stockholm, Sweden.
BMC Fam Pract. 2003 Apr 1;4:3. doi: 10.1186/1471-2296-4-3.
The indications for warfarin treatment in primary health care are increasing. An undertreatment with warfarin is reported in the prevention of embolic stroke in patients with chronic atrial fibrillation, and can be suspected for other indications. Information on the prevalence and incidence of diseases treated with warfarin would reveal useful data for audits concerning management of anticoagulant treatment. We aimed to assess warfarin treatment in primary health care with regard to prevalence, incidence, treatment diagnosis and patient characteristics.
A one-year retrospective study of electronic patient records up to May 2000 in primary health care in Stockholm, Sweden. Five primary health care centres with a registered population of 75 146. Main outcome measures were prevalence, incidence and treatment diagnosis.
Five hundred and seven patients, mean age 71.9 years, were on warfarin treatment. The prevalence was 0.67% (age-adjusted 0.75%), and it was significantly higher for men (0.78%) than for women (0.58%) (p = 0.01). In the age group 75-84 years the prevalence was 4.54%. The most prevalent treatment diagnosis was chronic atrial fibrillation (0.28%), which was more predominant for males (p = 0.02), followed by cerebrovascular disease (0.13%) and deep venous thrombosis (0.13%). The yearly incidence of warfarin treatment was 0.17%, with chronic atrial fibrillation as the predominant treatment diagnosis.
Warfarin treatment in primary health care is prevalent among the elderly. Chronic atrial fibrillation is the main treatment diagnosis. There is a gender difference favouring men in general and chronic atrial fibrillation as the treatment diagnosis.
在初级卫生保健中,华法林治疗的适应证正在增加。据报道,在慢性心房颤动患者预防栓塞性卒中方面,华法林治疗不足,其他适应证也可能存在这种情况。有关接受华法林治疗疾病的患病率和发病率信息,将为抗凝治疗管理的审计提供有用数据。我们旨在评估初级卫生保健中关于华法林治疗的患病率、发病率、治疗诊断和患者特征。
对瑞典斯德哥尔摩初级卫生保健机构截至2000年5月的电子病历进行为期一年的回顾性研究。五个初级卫生保健中心,登记人口为75146人。主要观察指标为患病率、发病率和治疗诊断。
507例患者接受华法林治疗,平均年龄71.9岁。患病率为0.67%(年龄调整后为0.75%),男性(0.78%)显著高于女性(0.58%)(p = 0.01)。在75 - 84岁年龄组中,患病率为4.54%。最常见的治疗诊断是慢性心房颤动(0.28%),男性更为多见(p = 0.02),其次是脑血管疾病(0.13%)和深静脉血栓形成(0.13%)。华法林治疗的年发病率为0.17%,主要治疗诊断为慢性心房颤动。
初级卫生保健中的华法林治疗在老年人中很普遍。慢性心房颤动是主要的治疗诊断。总体上存在性别差异,男性更易接受治疗,且治疗诊断以慢性心房颤动为主。